Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
3D Medicines is a commercial-stage oncology company with a leading PD-L1 monoclonal antibody (envafolimab) approved in China and a diverse late-stage pipeline including radiopharmaceuticals, mRNA cancer vaccines, and combination immunotherapies. Envafolimab showed rapid registration (NDA in <4 years after phase I) and is approved for MSI-H/dMMR advanced solid tumors. Pipeline assets address multiple solid tumor indications with both mono and combo strategies, and early radiopharmaceutical/mRNA platforms are in preclinical and early clinical development.[1][2][3][5][7]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 3D Medicines (Sichuan) Co., Ltd..